CPT-11 (irinotecan) in the treatment of colorectal cancer.
about
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitorsNew developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.Targeted therapies in colorectal cancer: surgical considerations.In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.CPT-11. The European experience.A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
P2860
Q33503456-4351337C-F99A-444F-B94D-5569CDD15756Q36114881-28EE3835-2724-4527-9661-59181B0F9B9CQ36291281-CDCB7471-FD49-4283-931A-1891161953C4Q36641418-ADA24FFF-FD56-4BED-9F19-6D8A89E546BAQ37015697-901CF1D9-189F-48FB-BECD-557A113FB741Q37381210-316ADC0B-DFE6-4666-BA09-FCA61267F437Q37437967-9C46354F-1008-4A02-A1E5-433DFCC5ECB3Q37441604-725CF6A2-701B-43A6-AB1B-2B106C30A0F0Q38393997-F7ADBB8D-55E8-4D50-A34F-F116E234FE80Q38894690-FEFBAF5F-906D-4B05-9CC0-FB3B2BBB3301Q39289157-2C026B7A-F481-4AE2-B8DF-D1120C5F90A3Q40916622-CE7F1287-8AE2-4D1D-B44E-87849616AF04Q40938391-536DA2FD-E2DE-430B-BFCF-54551F90DF42Q43274557-92ABC814-DCDA-489F-B877-B3A9DAA7295C
P2860
CPT-11 (irinotecan) in the treatment of colorectal cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
CPT-11 (irinotecan) in the treatment of colorectal cancer.
@en
type
label
CPT-11 (irinotecan) in the treatment of colorectal cancer.
@en
prefLabel
CPT-11 (irinotecan) in the treatment of colorectal cancer.
@en
P2093
P1476
CPT-11 (irinotecan) in the treatment of colorectal cancer.
@en
P2093
D Abigerges
J P Armand
M Mahjoubi
M de Forni
P304
P356
10.1016/0959-8049(95)00212-2
P577
1995-07-01T00:00:00Z